Recent Advances in the Treatment of Lung Cancer and Head & Neck Cancer

Approximately 292,360 new cases of lung, and head & neck cancers which include oral cavity/pharynx and thyroid glands have been diagnosed in 2009 in the United States, with nearly 168,620 resultant deaths. More than 85% of the patients have non-small cell lung cancer (NSCLC) histology. Approximately 40% of the patients will have IIIB or IV NSCLC, which is associated with a dismal median survival time of 8-12 months. The past decade has seen a paradigm shift in the treatment options for lung and head & neck cancers. This was facilitated through the concerted effort of research activity conducted through academic cancer institutions, and participating of community oncologists in the clinical trials. Nuances in the understanding of molecular mechanisms of lung, head & neck cancers have already led to therapeutic improvements. The outcome for patients with all stages of lung cancer has improved with the addition of novel cytotoxic agents, molecularly targeted drugs, and improved supportive care measures. A number of newer agents and targets are now being studied and will hopefully lead to further improvements in therapy.

Available until April 8, 2011

Please note: Nurses and pharmacists can go to www.internationalcancernetwork.com to complete the activity and receive credits.

Jointly Sponsored by International Lung Cancer Network and Postgraduate Institute for Medicine

This activity is supported by educational grants from Bristol-Myers Squibb/ImClone Systems, Genentech BioOncology, Lilly USA, LLC.
 

Module 1
Credit Hours	Credit Type
1.0	AMA PRA

 

Module 2
Credit Hours	Credit Type
.75	AMA PRA

 

Module 3
Credit Hours	Credit Type
.75	AMA PRA

 

Module 4
Credit Hours	Credit Type
1.0	AMA PRA

 

Module 5
Credit Hours	Credit Type
.5	AMA PRA

 

[Back to top]

[Back to Activity Home]